YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Options traders are buying the dip in two stocks this morning, with Meta Platforms (NASDAQ:META) and Vistagen Therapeutics (NASDAQ:VTGN) drawing bullish options activity as both equities trade lower. Meta Platforms stock is down 2.4% at $7…
SRX Global Inc SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones for fa…
(RTTNews) - Vistagen Therapeutics Inc. (VTGN), a late clinical-stage biopharmaceutical company developing intranasal pherine therapies for neuropsychiatric and other disorders, reported first quarter fiscal 2027 results and provided a corp…
* VistaGen Therapeutics press release [https://seekingalpha.com/pr/20619736-vistagen-reports-fiscal-year-2027-first-quarter-financial-results-and-corporate-update] (VTGN [https://seekingalpha.com/symbol/VTGN]): Q1 GAAP EPS of -$0.30 beats…
Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose Prespecified analysis of patients with ver…
Network technology ©Adobe Stock Images SRX Global (AMEX:SRXH) disclosed an investment in Vistagen Therapeutics (NASDAQ:VTGN) and said it intends to engage with the company's leadership and board on potential shareholder value initiatives.…
We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is one of the best psychedelic stocks on our list. TheFly reported on June 30 that VTGN announced topline…
Veeva Systems (VEEV) came out with quarterly earnings of $2.24 per share, beating the Zacks Consensus Estimate of $2.13 per share. This compares to earnings of $1.97 per share a year ago. These figures are adjusted for non-recurring items.…
Investors have long looked to Warren Buffett for investing inspiration. This is because the billionaire, as chief executive officer of Berkshire Hathaway for 60 years, led the company to market-beating returns over that time period. He did…
HealthEquity (HQY) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.97 per share a year ago. These figures are adjusted for non-recurring items. T…
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.22 per share a year ago. These figures are adjusted for non-recurring item…
Dr. Angelov brings extensive industry experience across multiple therapeutic areas SOUTH SAN FRANCISCO, Calif., May 19, 2026--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience…
NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) breached their fiduciary duties to share…
NEW YORK, March 14, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates i…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Vistagen between April 1, 2024…
LOS ANGELES, March 12, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (“Vistagen” or “the Company”) (NASDAQ: VTGN…
NEW YORK, March 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates i…
NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. (NASDAQ: VTGN) and…
NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates i…
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vistagen (VTGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired Vistagen common stock between April 1,…
SOUTH SAN FRANCISCO, Calif., March 03, 2026--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of in…
LOS ANGELES, March 02, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (“Vistagen” or “the Company”) (NASDAQ: VTGN…
ניו יורק, March 02, 2026 (GLOBE NEWSWIRE) -- מדוע: משרד רוזן עורכי דין (Rosen Law Firm), משרד עורכי דין בינלאומי העוסק בזכויות משקיעים, מזכיר לרוכשים את המניות הרגילות של Vistagen Therapeutics, Inc. (נאסד"ק: VTGN) בין התאריכים 1באפריל2024…
NEW YORK, March 01, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates i…
ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits: CoreWeave, Inc. (CRWV) The shareholder class action lawsuit fi…
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN). Such investors are advised to contact Danielle…
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates in…
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to r…
LOS ANGELES, Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (“Vistagen” or “the Company”) (NASDAQ: VTGN)…
NEW YORK, Feb. 21, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of PomDoctor, Ltd. (NASDAQ:POM…
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates in…
NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN). Shareholders who purchased shares of VTGN during the class period listed are encourag…
NEW YORK, Feb. 14, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates in…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Vistagen between April 1, 2024…
SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1…
LOS ANGELES, Feb. 13, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (“Vistagen” or “the Company”) (NASDAQ: VTGN)…